Conversion Chemotherapy for Unresectable Colorectal Liver Metastases

Are We Making a Difference?

Ali Mokdad, Michael A. Choti, Adam C. Yopp

Research output: Contribution to journalArticle

Abstract

Surgical resection remains the only curative therapy for colorectal liver metastases (CLM) with 5-year survival rates ranging from 40 to 58 %. Unfortunately, only approximately 15–25 % of patients are eligible for initial surgical resection. Among those that are unresectable, response to chemotherapy can convert an additional 15–20 % of unresectable patients to a potentially resectable state and offer curative-intent resection. In this select group of patients undergoing resection following conversion chemotherapy, 5-year survival rates approach 50 %. Despite a slightly shorter time to recurrence post-hepatectomy following conversion chemotherapy, these select patients have a significant survival advantage compared to palliative chemotherapy alone.

Original languageEnglish (US)
Pages (from-to)160-167
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume11
Issue number4
DOIs
StatePublished - May 6 2015
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Drug Therapy
Liver
Survival Rate
Hepatectomy
Recurrence
Survival
Therapeutics

Keywords

  • Colorectal carcinoma
  • Colorectal liver metastases
  • Hepatic resection
  • Systemic chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Conversion Chemotherapy for Unresectable Colorectal Liver Metastases : Are We Making a Difference? / Mokdad, Ali; Choti, Michael A.; Yopp, Adam C.

In: Current Colorectal Cancer Reports, Vol. 11, No. 4, 06.05.2015, p. 160-167.

Research output: Contribution to journalArticle

Mokdad, Ali ; Choti, Michael A. ; Yopp, Adam C. / Conversion Chemotherapy for Unresectable Colorectal Liver Metastases : Are We Making a Difference?. In: Current Colorectal Cancer Reports. 2015 ; Vol. 11, No. 4. pp. 160-167.
@article{3853285370a64945b375cb596d9a9b79,
title = "Conversion Chemotherapy for Unresectable Colorectal Liver Metastases: Are We Making a Difference?",
abstract = "Surgical resection remains the only curative therapy for colorectal liver metastases (CLM) with 5-year survival rates ranging from 40 to 58 {\%}. Unfortunately, only approximately 15–25 {\%} of patients are eligible for initial surgical resection. Among those that are unresectable, response to chemotherapy can convert an additional 15–20 {\%} of unresectable patients to a potentially resectable state and offer curative-intent resection. In this select group of patients undergoing resection following conversion chemotherapy, 5-year survival rates approach 50 {\%}. Despite a slightly shorter time to recurrence post-hepatectomy following conversion chemotherapy, these select patients have a significant survival advantage compared to palliative chemotherapy alone.",
keywords = "Colorectal carcinoma, Colorectal liver metastases, Hepatic resection, Systemic chemotherapy",
author = "Ali Mokdad and Choti, {Michael A.} and Yopp, {Adam C.}",
year = "2015",
month = "5",
day = "6",
doi = "10.1007/s11888-015-0271-8",
language = "English (US)",
volume = "11",
pages = "160--167",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Conversion Chemotherapy for Unresectable Colorectal Liver Metastases

T2 - Are We Making a Difference?

AU - Mokdad, Ali

AU - Choti, Michael A.

AU - Yopp, Adam C.

PY - 2015/5/6

Y1 - 2015/5/6

N2 - Surgical resection remains the only curative therapy for colorectal liver metastases (CLM) with 5-year survival rates ranging from 40 to 58 %. Unfortunately, only approximately 15–25 % of patients are eligible for initial surgical resection. Among those that are unresectable, response to chemotherapy can convert an additional 15–20 % of unresectable patients to a potentially resectable state and offer curative-intent resection. In this select group of patients undergoing resection following conversion chemotherapy, 5-year survival rates approach 50 %. Despite a slightly shorter time to recurrence post-hepatectomy following conversion chemotherapy, these select patients have a significant survival advantage compared to palliative chemotherapy alone.

AB - Surgical resection remains the only curative therapy for colorectal liver metastases (CLM) with 5-year survival rates ranging from 40 to 58 %. Unfortunately, only approximately 15–25 % of patients are eligible for initial surgical resection. Among those that are unresectable, response to chemotherapy can convert an additional 15–20 % of unresectable patients to a potentially resectable state and offer curative-intent resection. In this select group of patients undergoing resection following conversion chemotherapy, 5-year survival rates approach 50 %. Despite a slightly shorter time to recurrence post-hepatectomy following conversion chemotherapy, these select patients have a significant survival advantage compared to palliative chemotherapy alone.

KW - Colorectal carcinoma

KW - Colorectal liver metastases

KW - Hepatic resection

KW - Systemic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84934435317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934435317&partnerID=8YFLogxK

U2 - 10.1007/s11888-015-0271-8

DO - 10.1007/s11888-015-0271-8

M3 - Article

VL - 11

SP - 160

EP - 167

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 4

ER -